Merck Stops Trial of Pembrolizumab Plus Olaparib in Metastatic Castration-Resistant Prostate Cancer
March 16th 2022The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).
Read More
Pfizer and BioNTech Submit EUA for Additional Booster Dose of COVID-19 Vaccine for Older Adults
March 16th 2022Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.
Read More
FDA Approves BRACAnalysis CDx Companion Diagnostic Assay for Olaparib in Breast Cancer Treatment
March 15th 2022BRACAnalysis CDx assay is indicated for use as a companion diagnostic to select patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who may derive clinical benefit from olaparib.
Read More